Celldex Therapeutics (CLDX) Stock Price, Quote & News

Company Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhi...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 200 7500

Fax: 908 454 1911

Website: www.celldex.com

Address:

Perryville III Building, Suite 220 53 Frontage Road, Hampton, United States

Quantumup May. 29 at 12:18 PM

Cantor y'day⬆️ $SPRY's PT to $30 (was $12), reit'd OW ~Models ARS-2 for chronic spontaneous urticaria, w/ a '30 launch, w/ $575M in sales by '33 & pot'l to drive meaningful long-term upside if dev't/commercialization are successful. $CLDX $SNY - REGN NVS AQST TEVA Cantor said: We hosted a webinar to provide a more in-depth review of our work on SPRY's clinical program for CSU flares following our report yesterday. We believe this program represents a differentiated and under-appreciated opportunity that warrants greater investor attention. Based on our analysis and checks, we have a high degree of conviction in its likelihood of success.

0 · Reply

Timefortendies77 May. 26 at 9:40 PM

$CLDX PN update July/August

0 · Reply

Timefortendies77 May. 23 at 2:31 PM

$CLDX I've done the DD and looked at everything mast cell related. CLDX is #1 biggest potential biological out there at the moment. If they pass P3--this will change the lives of hundreds of thousands of people all over the world. If they have good results in PD (June/July) then this stock will moon as it will show the platform is wider than CINDU and CSU.

0 · Reply

Dont_Forget_The_Dates May. 22 at 12:56 PM

$CLDX is this an ASCO play?

1 · Reply

Timefortendies77 May. 20 at 4:49 PM

$CLDX This will be a big platform drug company--many indications 1 drug. They will get it right this time after recent failures.

0 · Reply

Timefortendies77 May. 20 at 12:31 AM

$CLDX PN P2 Top Line coming this summer. PN is a Billion Dollar market so success would be a big deal. Then the big CSU trial coming end of Q4.

0 · Reply

OfficialStocktwitsUser May. 19 at 6:48 PM

$CLDX RSI: 39.72, MACD: -0.3295 Vol: 1.19, MA20: 32.72, MA50: 32.07 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Arcides May. 18 at 4:31 PM

$CLDX becoming trash

0 · Reply

RunnerSignals May. 14 at 8:45 PM

$CLDX hard data moved first. price is catching up. we were already there

0 · Reply

anachartanalyst May. 13 at 4:02 PM

$CLDX https://anachart.com/wp-content/uploads/2026/05/1778688119_soc-img.jpg

0 · Reply

Celldex Therapeutics Slides: Corporate presentation

2026-05-13T11:08:49.000Z - 17 days ago

Celldex price target raised to $54 from $38 at Wells Fargo

2026-05-08T18:28:10.000Z - 21 days ago

Celldex price target raised to $38 from $34 at Goldman Sachs

2026-05-08T10:20:55.000Z - 22 days ago

Celldex price target raised to $48 from $45 at Barclays

2026-05-07T21:42:55.000Z - 22 days ago

Celldex sees funds sufficient to fund current planned operations through 2028

May 7, 2026, 4:01 PM EDT - 22 days ago

Celldex Reports First Quarter Financial Results and Provides Corporate Update

May 7, 2026, 4:00 PM EDT - 22 days ago

Celldex Therapeutics Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 22 days ago

Celldex Therapeutics Quarterly report: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 4 weeks ago

Celldex Therapeutics Proxy statement: Proxy filing

2026-04-20T14:19:17.000Z - 5 weeks ago

A Top Wall Street Analyst ‘Can’t Ignore’ Celldex Stock (CLDX)

2026-04-20T09:20:08.000Z - 5 weeks ago

Celldex upgraded to Overweight from Underweight at Barclays

Apr 14, 2026, 3:30 PM EDT - 6 weeks ago

Celldex Therapeutics Transcript: H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Apr 13, 2026, 4:01 PM EDT - 6 weeks ago

Celldex to Present at Upcoming Investor Conference

Apr 6, 2026, 10:53 AM EDT - 7 weeks ago

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 1, 2026, 9:48 PM EDT - 2 months ago

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

2026-04-01T20:11:56.000Z - 2 months ago

Celldex announces common stock offering, no amount given

Apr 1, 2026, 4:01 PM EDT - 2 months ago

Celldex Announces Proposed Public Offering of Common Stock

2026-03-27T14:35:13.000Z - 2 months ago

Celldex data shows improvements across six DLQI Domains in barzolvolimab trials

Mar 27, 2026, 10:30 AM EDT - 2 months ago

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

2026-03-23T09:45:08.000Z - 2 months ago

Celldex upgraded to Outperform from Peer Perform at Wolfe Research

Mar 10, 2026, 3:40 PM EDT - 2 months ago

Celldex Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 4, 2026, 9:10 AM EST - 3 months ago

Celldex Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-02T11:46:48.000Z - 3 months ago

Celldex price target raised to $34 from $30 at Goldman Sachs

2026-03-01T16:35:06.000Z - 3 months ago

Celldex presents new data from Phase 2 ColdU, SD Open Label Extension

Feb 27, 2026, 2:45 PM EST - 3 months ago

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

2026-02-26T14:45:31.000Z - 3 months ago

Celldex price target raised to $44 from $43 at Morgan Stanley

2026-02-26T12:40:18.000Z - 3 months ago

Celldex price target raised to $68 from $58 at Stifel

Feb 25, 2026, 4:01 PM EST - 3 months ago

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Feb 25, 2026, 4:00 PM EST - 3 months ago

Celldex Therapeutics Annual report: Q4 2025

Feb 25, 2026, 4:00 PM EST - 3 months ago

Celldex Therapeutics Earnings release: Q4 2025

2026-02-25T12:27:17.000Z - 3 months ago

Celldex completes enrollment in Phase 3 studies of barzolvolimab

Feb 25, 2026, 7:01 AM EST - 3 months ago

Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria

Feb 23, 2026, 8:01 AM EST - 3 months ago

Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile

Feb 11, 2026, 3:30 PM EST - 3 months ago

Celldex Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 9, 2026, 8:01 AM EST - 3 months ago

Celldex to Present at Upcoming Investor Conferences

2025-12-17T11:00:48.000Z - 5 months ago

Celldex price target raised to $24 from $21 at Barclays

Dec 9, 2025, 8:01 AM EST - 6 months ago

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

Dec 2, 2025, 3:00 PM EST - 6 months ago

Celldex Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 13, 2025, 9:30 AM EST - 7 months ago

Celldex Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 11, 2025, 10:00 AM EST - 7 months ago

Celldex Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:01 AM EST - 7 months ago

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

Nov 10, 2025, 12:00 AM EST - 7 months ago

Celldex Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 12:00 AM EST - 7 months ago

Celldex Therapeutics Earnings release: Q3 2025

Sep 17, 2025, 5:11 AM EDT - 9 months ago

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

Sep 9, 2025, 3:20 PM EDT - 9 months ago

Celldex Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 9:01 AM EDT - 9 months ago

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 19, 2025, 4:30 PM EDT - 10 months ago

Celldex Therapeutics Transcript: Study Update

Aug 19, 2025, 4:30 PM EDT - 10 months ago

Celldex Therapeutics Press release: Study Update

Aug 19, 2025, 4:01 PM EDT - 10 months ago

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Aug 7, 2025, 4:01 PM EDT - 10 months ago

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 4:00 PM EDT - 10 months ago

Celldex Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 10 months ago

Celldex Therapeutics Quarterly report: Q2 2025

Jun 14, 2025, 10:48 AM EDT - 1 year ago

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

Jun 12, 2025, 6:01 PM EDT - 1 year ago

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

Jun 12, 2025, 6:00 PM EDT - 1 year ago

Celldex Therapeutics Transcript: Status Update

Jun 12, 2025, 6:00 PM EDT - 1 year ago

Celldex Therapeutics Slides: Status Update

Jun 10, 2025, 4:01 PM EDT - 1 year ago

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

Jun 6, 2025, 8:01 AM EDT - 1 year ago

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

May 8, 2025, 4:01 PM EDT - 1 year ago

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 12:00 AM EDT - 1 year ago

Celldex Therapeutics Earnings release: Q1 2025

May 8, 2025, 12:00 AM EDT - 1 year ago

Celldex Therapeutics Quarterly report: Q1 2025

May 5, 2025, 4:01 PM EDT - 1 year ago

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Celldex Therapeutics Proxy statement: Proxy Filing

Mar 11, 2025, 1:00 PM EDT - 1 year ago

Celldex Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 1:50 PM EST - 1 year ago

Celldex Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 8:01 AM EST - 1 year ago

Celldex Therapeutics to Present at Upcoming Investor Conferences

Mar 3, 2025, 8:01 AM EST - 1 year ago

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

Mar 1, 2025, 12:45 PM EST - 1 year ago

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

Feb 27, 2025, 4:01 PM EST - 1 year ago

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 9:30 AM EST - 1 year ago

Celldex Therapeutics Annual report: Q4 2024

Feb 27, 2025, 9:30 AM EST - 1 year ago

Celldex Therapeutics Earnings release: Q4 2024

Dec 19, 2024, 8:01 AM EST - 1 year ago

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Dec 3, 2024, 4:15 PM EST - 1 year ago

Celldex Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 20, 2024, 8:01 AM EST - 1 year ago

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Nov 12, 2024, 4:00 PM EST - 1 year ago

Celldex Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 6, 2024, 4:01 PM EST - 1 year ago

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 6:00 PM EST - 1 year ago

Celldex Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 6:00 PM EST - 1 year ago

Celldex Therapeutics Earnings release: Q3 2024

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Celldex Therapeutics Transcript: Status Update

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Celldex Therapeutics Press release: Status Update

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Celldex Therapeutics Slides: Status Update

Oct 26, 2024, 5:43 PM EDT - 1 year ago

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

Oct 25, 2024, 8:01 AM EDT - 1 year ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

Oct 4, 2024, 7:00 AM EDT - 1 year ago

Celldex Therapeutics Slides: Corporate Presentation

Sep 25, 2024, 10:45 AM EDT - 1 year ago

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

Sep 20, 2024, 10:00 AM EDT - 1 year ago

Celldex Therapeutics Transcript: TD Cowen Chronic Urticaria Summit

Sep 17, 2024, 8:35 AM EDT - 1 year ago

Celldex Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 16, 2024, 8:01 AM EDT - 1 year ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Celldex Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Celldex Therapeutics Earnings release: Q2 2024

Jul 29, 2024, 4:30 PM EDT - 1 year ago

Celldex Therapeutics Transcript: Study Result

Jul 29, 2024, 4:30 PM EDT - 1 year ago

Celldex Therapeutics Press release: Study Result

Jul 29, 2024, 4:01 PM EDT - 1 year ago

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Jul 16, 2024, 8:01 AM EDT - 2 years ago

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Jun 4, 2024, 4:01 PM EDT - 2 years ago

Celldex Therapeutics to Present at Jefferies Healthcare Conference

Jun 2, 2024, 9:01 AM EDT - 2 years ago

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

May 15, 2024, 8:01 AM EDT - 2 years ago

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

May 6, 2024, 4:01 PM EDT - 2 years ago

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 6, 2024, 7:00 AM EDT - 2 years ago

Celldex Therapeutics Quarterly report: Q1 2024

May 6, 2024, 7:00 AM EDT - 2 years ago

Celldex Therapeutics Earnings release: Q1 2024

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Celldex Therapeutics Proxy statement: Proxy Filing

Apr 17, 2024, 8:01 AM EDT - 2 years ago

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Mar 8, 2024, 7:00 AM EST - 2 years ago

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 10:30 AM EST - 2 years ago

Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Feb 29, 2024, 9:14 PM EST - 2 years ago

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

Feb 28, 2024, 4:01 PM EST - 2 years ago

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Feb 26, 2024, 7:01 AM EST - 2 years ago

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 26, 2024, 7:00 AM EST - 2 years ago

Celldex Therapeutics Earnings release: Q4 2023

Feb 26, 2024, 7:00 AM EST - 2 years ago

Celldex Therapeutics Annual report: Q4 2023

Feb 25, 2024, 9:45 AM EST - 2 years ago

Celldex Therapeutics Transcript: Study Update

Feb 25, 2024, 9:45 AM EST - 2 years ago

Celldex Therapeutics Slides: Study Update

Feb 24, 2024, 2:05 PM EST - 2 years ago

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Feb 6, 2024, 4:01 PM EST - 2 years ago

Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 5, 2024, 8:01 AM EST - 2 years ago

Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024

Quantumup May. 29 at 12:18 PM

0 · Reply

Timefortendies77 May. 26 at 9:40 PM

$CLDX PN update July/August

0 · Reply

Timefortendies77 May. 23 at 2:31 PM

0 · Reply

Dont_Forget_The_Dates May. 22 at 12:56 PM

$CLDX is this an ASCO play?

1 · Reply

Timefortendies77 May. 20 at 4:49 PM

$CLDX This will be a big platform drug company--many indications 1 drug. They will get it right this time after recent failures.

0 · Reply

Timefortendies77 May. 20 at 12:31 AM

$CLDX PN P2 Top Line coming this summer. PN is a Billion Dollar market so success would be a big deal. Then the big CSU trial coming end of Q4.

0 · Reply

OfficialStocktwitsUser May. 19 at 6:48 PM

0 · Reply

Arcides May. 18 at 4:31 PM

$CLDX becoming trash

0 · Reply

RunnerSignals May. 14 at 8:45 PM

$CLDX hard data moved first. price is catching up. we were already there

0 · Reply

anachartanalyst May. 13 at 4:02 PM

$CLDX https://anachart.com/wp-content/uploads/2026/05/1778688119_soc-img.jpg

0 · Reply

Quantumup May. 13 at 11:32 AM

Wells Fargo⬆️the PT on $CLDX to $54 from $38, reiterated at Overweight, and said: We are getting more constructive on CLDX ahead of barzo's PN readout in mid-2026. $SNY - REGN $GALDY NVS JSPR Wells Fargo added—We believe the Street underappreciates the biological rationale, supportive Ph1b data and the role mast-cell depletion may play in the PN itch-scratch cycle. Barzo's Ph2 PN program appears well de-risked. KIT-driven mast cell depletion may disrupt the itch scratch cycle with added rationale from Nemluvio, which inhibits IL-31, a pruritogenic cytokine produced by mast cells and is approved in PN. Supportive Ph1b biomarker activity aligned with clinical responses, while early efficacy compared favorably vs. dupi/Nemluvio despite limited sample size and single-dose exposure. Durable CSU/ CIndU responses further support translational readthrough to PN.

0 · Reply

Timefortendies77 May. 12 at 2:19 PM

$CLDX CSU-Topline data are anticipated in Q4 2026, supporting a planned BLA filing in 2027. Phase 2 study in prurigo nodularis (PN)-Topline data from this study are expected to be presented in the summer of 2026 (guess June/July). Phase 2 study in atopic dermatitis (AD)-Topline data from this study are expected to be presented in late 2026.

0 · Reply

Timefortendies77 May. 12 at 2:10 PM

$CLDX Great company--but nothing to hold this up until summer updates, with the big update being end of year.

0 · Reply

Timefortendies77 May. 11 at 10:15 PM

$CLDX 60-100 end of year.

0 · Reply

lucabrix May. 10 at 7:12 PM

$CLDX “As we look ahead, our focus remains on execution—driving strong enrollment across our Phase 3 study in ColdU and SD and advancing towards multiple important data readouts this year,” Mr. Marucci continued. “These include topline data from our Phase 3 barzolvolimab CSU studies, results from Phase 2 studies in prurigo nodularis and atopic dermatitis, and additional data from our novel bispecific program, CDX-622.” 2027 will be glorious for CLDX!!!!!!

1 · Reply

free2dream May. 7 at 8:23 PM

$CLDX barzolvolimab will be bigger than $20B Dupixent. This will eventually be a $20B market cap company. Everyone loves a good comeback story and with the trial results being so superior, $CLDX price will appreciate BIG

1 · Reply

NJgolfer Apr. 30 at 10:51 PM

$CLDX big overhead resistance between $33.60 - $36. Probably not ready to breakout. Weekly MACD and Weekly Stochastics remain elevated but Chaikin MF/AD/OBV has turned down already. Once it eventually gets through $36, upside targets of $40 and $48

2 · Reply

Timefortendies77 Apr. 29 at 11:51 AM

$CLDX After trials finish this year, the market will wake up to the potential here---think of a XOLAIR on Steroids---we aren't talking about just suppression of the course of the disease/condition---we are talking about potentially changing the course of the disease/condition. Look at the people who stopped the drug and are still HIVE free---it is unprecedented. KIT drugs are basically like a Ferrari compared to the old Toyota Sedans of allergy meds.

0 · Reply

Estimize Apr. 28 at 1:00 PM

Wall St is expecting -1.15 EPS for $CLDX Q1 [Reporting 04/30 AMC] http://www.estimize.com/intro/cldx?chart=historical&metric_name=eps&utm_c

0 · Reply

RunnerSignals Apr. 28 at 3:30 AM

$INVA $CLDX $DNN $ILMN $NTCT all trading above ma50/200 with neutral-positive rsi that is early repricing not trapped capital

1 · Reply

Steve1545 Apr. 22 at 10:23 AM

$CLDX

1 · Reply

Estimize Apr. 21 at 1:00 PM

Wall St is expecting -1.20 EPS for $CLDX Q1 [Reporting 04/30 AMC] http://www.estimize.com/intro/cldx?chart=historical&metric_name=eps&utm_c

0 · Reply

Market Cap	2.49B
Revenue (ttm)	1.55M
Net Income (ttm)	-258.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-16,694.19%
Debt to Equity Ratio	0.00

Volume	494,600
Avg Vol	987,396
Day's Range	N/A - N/A
Shares Out	78.49M
Stochastic %K	71%
Beta	0.98
Analysts	Strong Sell
Price Target	$58.43